DK1200590T3 - C-type lectin-transmembran-antigen, der udtrykkes ved human prostatacancer, og anvendelser deraf - Google Patents

C-type lectin-transmembran-antigen, der udtrykkes ved human prostatacancer, og anvendelser deraf

Info

Publication number
DK1200590T3
DK1200590T3 DK00953992T DK00953992T DK1200590T3 DK 1200590 T3 DK1200590 T3 DK 1200590T3 DK 00953992 T DK00953992 T DK 00953992T DK 00953992 T DK00953992 T DK 00953992T DK 1200590 T3 DK1200590 T3 DK 1200590T3
Authority
DK
Denmark
Prior art keywords
prostate cancer
human prostate
antigen expressed
type lectin
transmembrane antigen
Prior art date
Application number
DK00953992T
Other languages
Danish (da)
English (en)
Inventor
Daniel E H Afar
Rene S Hubert
Aya Jakobovits
Arthur B Raitano
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Application granted granted Critical
Publication of DK1200590T3 publication Critical patent/DK1200590T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00953992T 1999-08-12 2000-08-11 C-type lectin-transmembran-antigen, der udtrykkes ved human prostatacancer, og anvendelser deraf DK1200590T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14893599P 1999-08-12 1999-08-12
PCT/US2000/022065 WO2001012811A1 (fr) 1999-08-12 2000-08-11 Antigene transmembranaire lectine du type c exprime dans le cancer humain de la prostate et ses utilisations

Publications (1)

Publication Number Publication Date
DK1200590T3 true DK1200590T3 (da) 2009-03-16

Family

ID=22528098

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08163095.6T DK1992695T3 (da) 1999-08-12 2000-08-11 Lectin-transmembran-antigen af type C udtrykt i human prostatacancer og avendelser deraf
DK00953992T DK1200590T3 (da) 1999-08-12 2000-08-11 C-type lectin-transmembran-antigen, der udtrykkes ved human prostatacancer, og anvendelser deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08163095.6T DK1992695T3 (da) 1999-08-12 2000-08-11 Lectin-transmembran-antigen af type C udtrykt i human prostatacancer og avendelser deraf

Country Status (13)

Country Link
US (6) US6602501B1 (fr)
EP (2) EP1200590B1 (fr)
JP (3) JP4373637B2 (fr)
AT (2) ATE420175T1 (fr)
AU (5) AU774436B2 (fr)
CA (1) CA2380550C (fr)
CY (2) CY1110256T1 (fr)
DE (2) DE60045201D1 (fr)
DK (2) DK1992695T3 (fr)
ES (2) ES2317846T3 (fr)
IL (3) IL147902A0 (fr)
PT (2) PT1992695E (fr)
WO (1) WO2001012811A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2005205754B2 (en) * 1999-03-23 2007-09-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE417063T1 (de) * 1999-03-23 2008-12-15 Genentech Inc Sekretierte transmembranproteine und dafür kodierende nukleinsäuren
EP1046651A1 (fr) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition et méthode pour moduler l'interaction des cellules dendritiques et les cellules T
DE60045201D1 (de) 1999-08-12 2010-12-16 Agensys Inc C-Typ-Lektin-Transmembran-Antigen, das in menschlichem Prostatakrebs exprimiert wird, und Verwendungen dieses Antigens
US7842458B2 (en) 1999-08-12 2010-11-30 Agensys, Inc. Nucleic acids and corresponding proteins entitled 58P1D12 useful in treatment and detection of cancer
US7449548B2 (en) 2001-12-07 2008-11-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
EP1778284B1 (fr) * 2004-08-16 2012-04-25 Agensys, Inc. Acides nucleiques et proteines correspondantes appeles 58p1d12 utiles dans la detection du cancer
US9492400B2 (en) * 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
GB0426822D0 (en) * 2004-12-07 2005-01-12 Precisense As Sensor for detection of glucose
GB0426823D0 (en) 2004-12-07 2005-01-12 Precisense As Sensor for detection of glucose
WO2007070682A2 (fr) * 2005-12-15 2007-06-21 Massachusetts Institute Of Technology Systeme de criblage de particules
CA2648099C (fr) * 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc Systeme pour l'administration ciblee d'agents therapeutiques
EP2019691B1 (fr) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymères pour particules fonctionnelles
WO2007137117A2 (fr) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Administration de médicaments dirigée par aptamères
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
EP2134830A2 (fr) * 2007-02-09 2009-12-23 Massachusetts Institute of Technology Bioréacteur oscillant pour la culture de cellules
WO2008124632A1 (fr) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Nanoparticules assistées par des composés amphiphiles pour délivrance ciblée
WO2008124634A1 (fr) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Micelles inverses encapsulées par un polymère
CA2917512C (fr) 2007-10-12 2025-08-05 President And Fellows Of Harvard College Nanotechnologie des vaccins
WO2010022279A1 (fr) * 2008-08-20 2010-02-25 Agensys, Inc. Anticorps et molécules associées qui se lient à des protéines 58p1d12
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
CN105238781B (zh) * 2015-11-06 2018-02-16 福建省农业科学院果树研究所 基于转录组序列开发的李ssr标记引物对及其应用
US10543288B2 (en) 2017-04-28 2020-01-28 Medtronic Minimed, Inc. Modified-dextrans for use in optical glucose assays
US10792378B2 (en) 2017-04-28 2020-10-06 Medtronics Minimed, Inc. Using a blue-shifted reference dye in an optical glucose assay

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US4975287A (en) 1989-09-01 1990-12-04 Wm. Wrigley Jr. Company Gum composition containing protein macrocolloids
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
WO1992000311A1 (fr) 1990-06-27 1992-01-09 Princeton University Sondes de detection de p53 mutant
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5879898A (en) * 1992-11-20 1999-03-09 Isis Innovation Limited Antibodies specific for peptide corresponding to CD44 exon 6, and use of these antibodies for diagnosis of tumors
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
EP0773952B1 (fr) 1994-07-20 2003-11-12 The General Hospital Corporation Systemes de detection d'interactions entre proteines
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
NZ502795A (en) 1995-04-11 2001-09-28 Gen Hospital Corp Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US5681923A (en) * 1995-10-06 1997-10-28 Platt; David Tumor derived carbohydrate binding protein
US6476192B1 (en) * 1996-04-15 2002-11-05 Nicola C. Lally Recombinant antigens useful for the serodiagnosis of neosporosis
US6117977A (en) * 1996-04-24 2000-09-12 Genentech, Inc. Type C lectins
WO1997041255A1 (fr) 1996-04-26 1997-11-06 Massachusetts Institute Of Technology Methode de criblage a l'aide de trois hybrides
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
EP0953039B1 (fr) 1996-10-15 2007-08-29 The Regents Of The University Of California Modeles animaux de la progression du cancer de la prostate chez l'humain
US5846722A (en) 1996-10-16 1998-12-08 Terrapin Technologies, Inc. System to detect small molecule/peptide interaction
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7435793B2 (en) 1998-05-15 2008-10-14 Genentech, Inc. Peptides that induce chondrocyte redifferentiation
US20030004311A1 (en) 1997-06-18 2003-01-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030022239A1 (en) 1997-06-18 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030087344A1 (en) 1997-06-18 2003-05-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030166104A1 (en) 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030104538A1 (en) 1997-09-18 2003-06-05 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7160985B2 (en) 1997-10-29 2007-01-09 Genentech, Inc. Pro180 polypeptide
US7105639B2 (en) 1998-05-15 2006-09-12 Genentech, Inc. Anti-PRO 4405 antibodies
EP1082341B1 (fr) 1998-06-01 2010-12-08 Agensys, Inc. Nouvel antigene tumoral utile dans le diagnostic et la therapie propres au cancer de la prostate et du colon
EP1100869A4 (fr) 1998-07-30 2005-04-27 Human Genome Sciences Inc 98 proteines humaines secretees
US20030050465A1 (en) 1998-08-10 2003-03-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000039296A1 (fr) * 1998-12-23 2000-07-06 Immunex Corporation Polypeptides et adn s3939 de lectine
US20030190669A1 (en) 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE417063T1 (de) * 1999-03-23 2008-12-15 Genentech Inc Sekretierte transmembranproteine und dafür kodierende nukleinsäuren
EP1074617A3 (fr) 1999-07-29 2004-04-21 Research Association for Biotechnology Amorces pour la synthèse de cADN de pleine longueur et leur utilisation
DE60045201D1 (de) 1999-08-12 2010-12-16 Agensys Inc C-Typ-Lektin-Transmembran-Antigen, das in menschlichem Prostatakrebs exprimiert wird, und Verwendungen dieses Antigens
CA2380355A1 (fr) 1999-09-01 2001-03-08 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
US7555263B1 (en) * 1999-10-21 2009-06-30 Broadcom Corporation Adaptive radio transceiver
EP1666494A1 (fr) 1999-12-01 2006-06-07 Genentech, Inc. Polypeptides secretés et transmembranaires et acides nucléiques les codant
US7300758B2 (en) 1999-12-09 2007-11-27 Genetech, Inc. Nucleic acid underexpressed in esophageal tumor
WO2001055321A2 (fr) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
US20020081590A1 (en) 2000-02-04 2002-06-27 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
JP3467264B2 (ja) * 2000-03-21 2003-11-17 三菱レイヨン株式会社 微生物の培養法
WO2001077291A2 (fr) 2000-04-06 2001-10-18 Genetics Institute, Llc. Polynucleotides codant pour de nouvelles proteines secretees
CA2412211A1 (fr) 2000-06-23 2002-01-03 Genetech, Inc. Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
JP2004516013A (ja) 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド 血管形成に関連する障害を診断及び治療するための組成物と方法
US20030165843A1 (en) 2000-07-28 2003-09-04 Avi Shoshan Oligonucleotide library for detecting RNA transcripts and splice variants that populate a transcriptome
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
US7250495B2 (en) 2001-06-20 2007-07-31 Genentech, Inc. PRO20044 polypeptides
JP3921367B2 (ja) * 2001-09-26 2007-05-30 日本電気株式会社 データ処理装置および方法、コンピュータプログラム、情報記憶媒体、並列演算装置、データ処理システム
US20030018172A1 (en) 2001-12-06 2003-01-23 Genentech, Inc. Secreted transmembrane polypeptides and nucleic acids encoding the same
JP2004187620A (ja) 2002-12-13 2004-07-08 Sumitomo Pharmaceut Co Ltd 腎疾患の疾患マーカーおよびその利用
US20090068098A1 (en) * 2007-08-20 2009-03-12 Kanner Steven B Antibodies and related molecules that bind to 58p1d12 proteins

Also Published As

Publication number Publication date
EP1992695A3 (fr) 2009-01-07
EP1992695B1 (fr) 2010-11-03
JP2003507042A (ja) 2003-02-25
IL197988A (en) 2011-12-29
US20100028374A1 (en) 2010-02-04
DK1992695T3 (da) 2011-02-14
IL147902A (en) 2011-04-28
AU2004203513B2 (en) 2006-05-11
AU2004203513A1 (en) 2004-08-26
AU6635100A (en) 2001-03-13
ATE420175T1 (de) 2009-01-15
PT1200590E (pt) 2009-03-24
EP1200590A1 (fr) 2002-05-02
CA2380550A1 (fr) 2001-02-22
EP1992695A2 (fr) 2008-11-19
AU774436B2 (en) 2004-06-24
PT1992695E (pt) 2011-01-12
US20070092918A1 (en) 2007-04-26
US7598045B2 (en) 2009-10-06
AU2009200299B2 (en) 2011-12-22
US6602501B1 (en) 2003-08-05
AU2006203476A1 (en) 2006-08-31
US20050019872A1 (en) 2005-01-27
CA2380550C (fr) 2011-02-01
JP2009235109A (ja) 2009-10-15
CY1111147T1 (el) 2015-06-11
JP4373637B2 (ja) 2009-11-25
AU2009200576A1 (en) 2009-03-05
IL147902A0 (en) 2002-08-14
US20040038271A1 (en) 2004-02-26
ATE486938T1 (de) 2010-11-15
JP2006204306A (ja) 2006-08-10
ES2355428T3 (es) 2011-03-25
WO2001012811A1 (fr) 2001-02-22
ES2317846T3 (es) 2009-05-01
US7148337B2 (en) 2006-12-12
DE60045201D1 (de) 2010-12-16
US7153940B2 (en) 2006-12-26
US7087718B2 (en) 2006-08-08
US20040265898A1 (en) 2004-12-30
EP1200590B1 (fr) 2009-01-07
US8022174B2 (en) 2011-09-20
AU2009200576B2 (en) 2011-12-22
DE60041333D1 (de) 2009-02-26
CY1110256T1 (el) 2015-01-14
AU2009200299A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
IL147902A0 (en) C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
WO2004113571A3 (fr) Genes specifiques de la prostate et leur utilisation comme cibles dans le traitement et le diagnostic du cancer de la prostate
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
WO2002046477A3 (fr) Retrovirus endogenes regules positivement dans le cancer de la prostate
TW428026B (en) Bifunctional protein, preparation and use
WO2002089747A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
DE69942031D1 (de) In prostatakrebs exprimiertes gen
WO2003070889A3 (fr) Genes specifiques de la prostate et leur utilisation dans la conception ou la therapie
IL207012A (en) 28sgp medicinal product and 28sgp accent cancer treatment vaccine
AU4174201A (en) 103p2d6: tissue specific protein highly expressed in various cancers
ATE501255T1 (de) 84p2a9: prostata- und hodenspezifisches protein, das sehr stark bei prostatakrebs vorkommt
WO2003080800A3 (fr) Prevention et traitement de maladies au moyen d'angiogenese et/ou d'antigenes tumoraux
EP1351967A4 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer des poumons
WO2003020954A3 (fr) Acide nucleique et proteine correspondante appelee 205p1b5 utilises dans le traitement et la detection du cancer
WO2002094201A3 (fr) Composition et methode de traitement de cellules
WO2001059110A3 (fr) 34p3d7: proteine specifique aux tissus hautement exprimes dans le cancer de la prostate
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
WO2001059115A3 (fr) Le 83p5g4: proteine specifique de tissus fortement exprime dans le cancer de la prostate
WO2003020294A8 (fr) Marquage d'aromatase
WO2002085286A3 (fr) Procedes permettant d'utiliser la chimiokine d'organes lymphoides secondaires pour moduler des processus physiologiques chez des mammiferes
AU2002366631A1 (en) Human prostate cancer candidate protein 1
AU2002243918A1 (en) Methods for the treatment and diagnosis of prostate cancer based on p75ntr tumor
TW200635950A (en) Specific binding agents of human angiopoietin-2